Bruton's tyrosine kinase inhibitors: Approaches to potent and selective inhibition, preclinical and clinical evaluation for inflammatory diseases and B cell malignancies

Journal of Medicinal Chemistry

Volumn 55, Issue 10, 2012, Pages 4539-4550

  Lou, Yan ^a   Owens, Timothy D ^a,b   Kuglstatter, Andreas ^a,c   Kondru, Rama K ^a   Goldstein, David M ^a,b  

^a HOFFMANN LA ROCHE INC   (United States)

^b Principia Biopharma   (United States)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

2 CYANO N (2,5 DIBROMOPHENYL) 3 HYDROXYCROTONAMIDE; AVL 101; B 43; BRUTON TYROSINE KINASE; BRUTON TYROSINE KINASE INHIBITOR; CGI 1746; DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; FOSTAMATINIB; IBRUTINIB; IMATINIB; JANUS KINASE 3; METHOTREXATE; PCI 29732; PCI 45292; RN 486; UNCLASSIFIED DRUG;

ARTHRITIS; CHRONIC LYMPHATIC LEUKEMIA; CRYSTAL STRUCTURE; DRUG POTENCY; DRUG PROTEIN BINDING; ENZYME INHIBITION; HEMATOLOGIC MALIGNANCY; HUMAN; INFLAMMATORY DISEASE; MANTLE CELL LYMPHOMA; NONHODGKIN LYMPHOMA; NONHUMAN; REVIEW; SMALL LYMPHOCYTIC LYMPHOMA; TUMOR MICROENVIRONMENT;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC AGENTS; CATALYTIC DOMAIN; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; DRUG INDUSTRY; HUMANS; INFLAMMATION; LEUKEMIA, B-CELL; MODELS, MOLECULAR; PROTEIN CONFORMATION; PROTEIN-TYROSINE KINASES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84861501740     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm300035p     Document Type: Review

References (79)

1. Vetrie, D.; Vorechovsky, I.; Sideras, P.; Holland, J.; Davies, A.; Flinter, F.; Hammarstrom, L.; Kinnon, C.; Levinsky, R.; Bobrow, M.; Smith, C. I. E.; Bentley, D. R. The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases Nature 1993, 361, 226-233 (Pubitemid 23034471)
2. Smith, C. I.; Baskin, B.; Humire-Greiff, P.; Zhou, J. N.; Olsson, P. G.; Maniar, H. S.; Kjellen, P.; Lambris, J. D.; Christensson, B.; Hammarstrom, L.; Bentley, D.; Vetrie, D.; Islam, K. B.; Vorechovsky, I.; Sideras, P. Expression of Bruton's agammaglobulinemia tyrosine kinase gene, BTK, is selectively down-regulated in T lymphocytes and plasma cells J. Immunol. 1994, 152, 557-565 (Pubitemid 24072959)
3. Conley, M. E.; Dobbs, A. K.; Farmer, D. M.; Kilic, S.; Paris, K.; Grigoriadou, S.; Coustan-Smith, E.; Howard, V.; Campana, D. Primary B cell immunodeficiencies: comparisons and contrasts Annu. Rev. Immunol. 2009, 27, 199-227
4. Gürcan, H. M.; Keskin, D. B.; Stern, J. N. H.; Nitzberg, M. A.; Shekhani, H.; Ahmed, A. R. Int. Immunopharmacol. 2009, 9, 10-25
5. Davis, R. E.; Ngo, V. N.; Lenz, G.; Tolar, P.; Young, R. M.; Romesser, P. B.; Kohlhammer, H.; Lamy, L.; Zhao, H.; Yang, Y.; Xu, W.; Shaffer, A. L.; Wright, G.; Xiao, W.; Powell, J.; Jiang, J. K.; Thomas, C. J.; Rosenwald, A.; Ott, G.; Muller-Hermelink, H. K.; Gascoyne, R. D.; Connors, J. M.; Johnson, N. A.; Rimsza, L. M.; Campo, E.; Jaffe, E. S.; Wilson, W. H.; Delabie, J.; Smeland, E. B.; Fisher, R. I.; Braziel, R. M.; Tubbs, R. R.; Cook, J. R.; Weisenburger, D. D.; Chan, W. C.; Pierce, S. K.; Staudt, L. M. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma Nature 2010, 463, 88-92
6. Mohamed, A. J.; Yu, L.; Backesjo, C. M.; Vargas, L.; Faryal, R.; Aints, A.; Christensson, B.; Berglof, A.; Vihinen, M.; Nore, B. F.; Smith, C. I. Bruton's tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain Immunol. Rev. 2009, 228, 58-73
7. Pan, Z. Bruton's tyrosine kinase as a drug discovery target Drug News Perspect. 2008, 21, 357-362
8. Rokosz, L. L.; Beasley, J. R.; Carroll, C. D.; Lin, T.; Zhao, J.; Appell, K. C.; Webb, M. L. Kinase inhibitors as drugs for chronic inflammatory and immunological diseases: progress and challenges Expert Opin. Ther. Targets 2008, 12, 883-903 (Pubitemid 352003327)
9. Uckun, F. M.; Tibbles, H. E.; Vassilev, A. O. Bruton's tyrosine kinase as a new therapeutic target Anti-Cancer Agents Med. Chem. 2007, 7, 624-632 (Pubitemid 350237767)
10. Knight, Z. A.; Shokat, K. M. Features of selective kinase inhibitors Chem. Biol. 2005, 12, 621-637 (Pubitemid 43142039)
11. Thaimattam, R.; Banerjee, R.; Miglani, R.; Iqbal, J. Protein kinase inhibitors: structural insights into selectivity Curr. Pharm. Des. 2007, 13, 2751-2765 (Pubitemid 350130972)
12. Potashman, M. H.; Duggan, M. E. Covalent modifiers: an orthogonal approach to drug design J. Med. Chem. 2009, 52, 1231-1246
13. Singh, J.; Petter, R. C.; Baillie, T. A.; Whitty, A. The resurgence of covalent drugs Nat. Rev. Drug Discovery 2011, 10, 307-317
14. Singh, J.; Petter, R. C.; Kluge, A. F. Targeted covalent drugs of the kinase family Curr. Opin. Chem. Biol. 2010, 14, 475-480
15. Mao, C.; Zhou, M.; Uckun, F. M. Crystal structure of Bruton's tyrosine kinase domain suggests a novel pathway for activation and provides insights into the molecular basis of X-linked agammaglobulinemia J. Biol. Chem. 2001, 276, 41435-41443
16. Marcotte, D. J.; Liu, Y. T.; Arduini, R. M.; Hession, C. A.; Miatkowski, K.; Wildes, C. P.; Cullen, P. F.; Hong, V.; Hopkins, B. T.; Mertsching, E.; Jenkins, T. J.; Romanowski, M. J.; Baker, D. P.; Silvian, L. F. Structures of human Bruton's tyrosine kinase in active and inactive conformations suggest a mechanism of activation for TEC family kinases Protein Sci. 2010, 19, 429-439
17. Kuglstatter, A.; Wong, A.; Tsing, S.; Lee, S. W.; Lou, Y.; Villasenor, A. G.; Bradshaw, J. M.; Shaw, D.; Barnett, J. W.; Browner, M. F. Insights into the conformational flexibility of Bruton's tyrosine kinase from multiple ligand complex structures Protein Sci. 2011, 20, 428-436
18. Di Paolo, J. A.; Huang, T.; Balazs, M.; Barbosa, J.; Barck, K. H.; Bravo, B. J.; Carano, R. A.; Darrow, J.; Davies, D. R.; DeForge, L. E.; Diehl, L.; Ferrando, R.; Gallion, S. L.; Giannetti, A. M.; Gribling, P.; Hurez, V.; Hymowitz, S. G.; Jones, R.; Kropf, J. E.; Lee, W. P.; Maciejewski, P. M.; Mitchell, S. A.; Rong, H.; Staker, B. L.; Whitney, J. A.; Yeh, S.; Young, W. B.; Yu, C.; Zhang, J.; Reif, K.; Currie, K. S. Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis Nat. Chem. Biol. 2011, 7, 41-50
19. Cowan-Jacob, S. W.; Mobitz, H.; Fabbro, D. Structural biology contributions to tyrosine kinase drug discovery Curr. Opin. Cell Biol. 2009, 21, 280-287
20. Capdeville, R.; Buchdunger, E.; Zimmermann, J.; Matter, A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug Nat. Rev. Drug Discovery 2002, 1, 493-502
21. Goldstein, D. M.; Kuglstatter, A.; Lou, Y.; Soth, M. J. Selective p38alpha inhibitors clinically evaluated for the treatment of chronic inflammatory disorders J. Med. Chem. 2010, 53, 2345-2353
22. Mahajan, S.; Ghosh, S.; Sudbeck, E. A.; Zheng, Y.; Downs, S.; Hupke, M.; Uckun, F. M. Rational design and synthesis of a novel anti-leukemic agent targeting Bruton's tyrosine kinase (BTK), LFM-A13 [alpha-cyano-beta-hydroxy- beta-methyl- N -(2,5-dibromophenyl)propenamide] J. Biol. Chem. 1999, 274, 9587-9599
23. Pan, Z.; Scheerens, H.; Li, S. J.; Schultz, B. E.; Sprengeler, P. A.; Burrill, L. C.; Mendonca, R. V.; Sweeney, M. D.; Scott, K. C.; Grothaus, P. G.; Jeffery, D. A.; Spoerke, J. M.; Honigberg, L. A.; Young, P. R.; Dalrymple, S. A.; Palmer, J. T. Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase ChemMedChem 2007, 2, 58-61
24. Honigberg, L. A.; Smith, A. M.; Sirisawad, M.; Verner, E.; Loury, D.; Chang, B.; Li, S.; Pan, Z.; Thamm, D. H.; Miller, R. A.; Buggy, J. J. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy Proc. Natl. Acad. Sci. U.S.A. 2010, 107, 13075-13080
25. Xu, W.; Doshi, A.; Lei, M.; Eck, M. J.; Harrison, S. C. Crystal structures of c-Src reveal features of its autoinhibitory mechanism Mol. Cell 1999, 3, 629-638 (Pubitemid 29268446)
26. Schindler, T.; Sicheri, F.; Pico, A.; Gazit, A.; Levitzki, A.; Kuriyan, J. Crystal structure of Hck in complex with a Src family-selective tyrosine kinase inhibitor Mol. Cell 1999, 3, 639-648 (Pubitemid 29268447)
27. Kutach, A. K.; Villasenor, A. G.; Lam, D.; Belunis, C.; Janson, C.; Lok, S.; Hong, L. N.; Liu, C. M.; Deval, J.; Novak, T. J.; Barnett, J. W.; Chu, W.; Shaw, D.; Kuglstatter, A. Crystal structures of IL-2-inducible T cell kinase complexed with inhibitors: insights into rational drug design and activity regulation Chem. Biol. Drug Des. 2010, 76, 154-163
28. Chen, W.; Loury, D. J.; Mody, T. D.; Verner, E.; Smyth, M. S.; Luo, W. Preparation of Pyrazolo-pyrimidine Compounds as Inhibitors of Bruton's Tyrosine Kinase. Patent Application WO 2011/046964, 2011.
29. Honigberg, L.; Verner, E.; Buggy, J.; Loury, D.; Chen, W. Preparation of Substituted Pyrazolopyrimidinamines as Inhibitors of Bruton's Tyrosine Kinase. Patent Application WO 2010/009342, 2010.
30. Honigberg, L.; Verner, E.; Buggy, J. J.; Loury, D.; Chen, W. Preparation of Substituted Pyrazolopyrimidinamines As Therapeutic Inhibitors of Bruton's Tyrosine Kinase and Other Kinases. Patent Application WO 2008/121742, 2008.
31. Honigberg, L.; Verner, E.; Pan, Z. Preparation of Substituted Pyrazolopyrimidinamines as Inhibitors of Bruton's Tyrosine Kinase. Patent Application US 2008/0108636, 2008.
32. Honigberg, L.; Verner, E.; Pan, Z. Preparation of 1 H -Pyrazolo[3,4- d ]pyrimidine Derivatives as Bruton's Tyrosine Kinase Inhibitors. Patent Application US 2008/0076921, 2008.
33. Pan, Z.; Li, S. J.; Schereens, H.; Honigberg, L.; Verner, E. Inhibitor-Derived Reporter Molecules for Detection of Bruton's Tyrosine Kinase and Their Uses. Patent Application WO 2008/054827, 2008.
34. ClinicalTrials.gov. Safety and Efficacy of PCI-32765 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (MCL) (PCYC-1104-CA). http://clinicaltrials.gov/ct2/show/NCT01236391 (accessed Aug 25, 2011).
35. Byrd, J. C.; Blum, K. A.; Burger, J. A.; Coutre, S. E.; Sharman, J. R.; Furman, R. R.; Flinn, I. W.; Grant, B. W.; Richards, D. A.; Zhao, W.; Heerema, N. A.; Johnson, A. J.; Izumi, R.; Hamdy, A.; O'Brien, S. M. Activity and Tolerability of the Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Interim Results of a Phase Ib/II Study. Presented at the 2011 ASCO Annual Meeting, Chicago, IL, 2011; Poster 6508.
36. Advani, R.; Porte Sharman, J.; Smith, S.; Boyd, T.; Grant, B.; Kolibaba, K.; Furman, R.; Buggy, J.; Loury, D.; Hedrick, E.; Izumi, R.; Hamdy, A.; Fowler, N. The Btk Inhibitor PCI-32765 Is Highly Active and Well Tolerated in Patients with Relapsed/Refractory B Cell Malignancies: Final Results from a Phase I Study. Presented at the 11th International Conference on Malignant Lymphoma, ICML, Palazzo dei Congressi, Lugano, Switzerland, 2011.
37. O'Brien, S.; Burger, J. A.; Coutre, S. E.; Porte Sharman, J.; Furman, R. R.; Flinn, I. W.; Grant, B.; Richards, D.; Heerema, N.; Johnson, A. J.; Izumi, R.; Hamdy, A.; Blum, K. A.; Byrd, J. C. The Btk Inhibitor PCI-32765 Is Highly Active and Tolerable in Patients with Poor-Risk CLL: Interim Results from a Phase Ib/II Study. Presented at the 11th International Conference on Malignant Lymphoma, ICML, Palazzo dei Congressi, Lugano, Switzerland, 2011.
38. Pollyea, D. A.; Smith, S.; Fowler, N.; Boyd, T.; Smith, A. M.; Sirisawad, M.; Honigberg, L. A.; Hamdy, A.; Advani, R. A Phase I Dose Escalation Study of the Btk Inhibitor PCI-32765 in Relapsed and Refractory B Cell Non-Hodgkin Lymphoma and Use of a Novel Fluorescent Probe Pharmacodynamic Assay. Presented at the 51st ASH Annual Meeting and Exposition, New Orleans, LA, 2009; Poster 3713.
39. Fowler, N.; Sharman, J. P.; Smith, S. S.; Boyd, T.; Grant, B.; Kolibaba, K. S.; Furman, R. R.; Buggy, J.; Loury, D.; Hamdy, A.; Advani, R. The BTK Inhibitor, PCI-32765, Induces Durable Responses with Minimal Toxicity in Patients with Relapsed/Refractory B-Cell Malignancies: Results from a Phase I Study. Presented at the 52nd ASH Annual Meeting and Exposition, Orlando, FL, 2010.
40. de Rooij, M. F. M.; Kuil, A.; Geest, C. R.; Eldering, E.; Chang, B. Y.; Buggy, J. J.; Pals, S. T.; Spaargaren, M. The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood [Online early access]. DOI: 10.1182/blood-2011-11-390989. Published Online: Jan 25, 2012
41. ClinicalTrials.gov. Safety and Efficacy Study of Bruton's Tyrosine Kinase Inhibitor in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. http://clinicaltrials.gov/ct2/show/NCT01325701?term=PCI- 32765&rank=7 (accessed Aug 25, 2011).
42. ClinicalTrials.gov. Safety and Tolerability Study of PCI-32765 Combined with Fludarabine/Cyclophosphamide/Rituximab (FCR) and Bendamustine/Rituximab (BR) in Chronic Lymphocytic Leukemia (CLL). http://clinicaltrials.gov/ct2/show/ NCT01292135 (accessed Aug 25, 2011).
43. Hattori, K.; Wakabayashi, H.; Tamaki, K. Predicting key example compounds in competitors' patent applications using structural information alone J. Chem. Inf. Model. 2008, 48, 135-142 (Pubitemid 351271058)
44. Chang, B. Y.; Thiemann, P.; Francesco, M.; Huang, M. M.; Sirisawad, M.; Purro, N.; Jejurkar, P.; Mani, C.; Tonev, D.; Chen, W.; Buggy, J. J.; Loury, D. J. PCI-45292, a novel Btk inhibitor with optimized pharmaceutical properties, demonstrates potent activities in mouse models of arthritis Arthritis Rheum. 2010, 62 (Suppl. 10) 286 (Abstract)
45. Pharmacyclics. Update on Preclinical Finding and Development Timeline for PCI-45292. http://ir.pharmacyclics.com/releasedetail.cfm?ReleaseID=553831 (accessed Aug 25, 2011).
46. Kluge, A. F.; Petter, R. C.; Tester, R. W.; Qiao, L.; Niu, D.; Westlin, W. F.; Singh, J.; Mazdiyasni, H. Heteroaryl Compounds and Uses Thereof. Patent Application WO 2009/158571, 2009.
47. Singh, J.; Ghosh, S.; Kluge, A. F.; Petter, R. C.; Tester, R. W. Heteroaryl Compounds and Uses Thereof. Patent Application US 2010/0016296, 2010.
48. Singh, J.; Petter, R. C.; Tester, R. W.; Kluge, A. F.; Mazdiyasni, H.; Westlin, W. F.; Niu, D.; Qiao, L. Heteroaryl Compounds and Uses Thereof. Patent Application US 2010/0249092, 2010.
49. Singh, J.; Petter, R. C.; Niu, D. Algorithm for Designing Irreversible Inhibitors. Patent Application WO 2010/028236, 2010.
50. Evans, E.; Sheets, M.; Bernard, H.; Martin, T. S.; Nacht, M.; Zhu, Z.; Tester, R.; Mazdiyasni, H.; Chaturvedi, P.; Petter, R.; Westlin, W.; Singh, J. Prolonged Inhibition of BCR Signaling and Suppression of B Cell Lymphoma through Irreversible Inhibition of Bruton's Tyrosine Kinase. Presented at the 50th American Society of Hematology Annual Meeting and Exposition, San Francisco, CA, 2008; Poster 2608.
51. Karp, R.; Evans, E.; Aslanian, S.; Chaturvedi, P.; Mazdiyasni, H.; Nacht, M.; Petter, R.; Sheets, M.; Singh, J.; Tester, R.; Westlin, W. Inhibition of BTK with AVL-292 Translates to Protective Activity in Rodent Models of Rheumatoid Arthritis. Presented at the 16th International IRA Conference Meeting, Chantilly, VA, 2010; Poster A113.
52. Evans, E.; Tester, R; Mazdiyasni, H.; Ponader, S.; Tesar, B.; Chaturavedi, P.; Nacht, M.; Stiede, S.; Witowski, S.; Lounsbury, H.; Silver, B.; Burger, J.; Brown, J. R.; Mahadevan, D.; Sharman, J.; Harb, W.; Petter, R.; Singh, J.; Westlin, W. Clinical Development of AVL-292: A Potent, Selective Covalent Btk Inhibitor for the Treatment of B Cell Malignancies. Presented at the 53rd American Society of Hematology (ASH) Annual Meeting and Exposition, San Diego, CA, 2011; Poster 3485.
53. Konteatis, Z.; Moffett, K.; Lee, Y.; Chao, W. Pyrrolotriazine compounds. Patent Application WO 2010/126960, 2010.
54. Kim, K. H.; Maderna, A.; Schnute, M. E.; Hegen, M.; Mohan, S.; Miyashiro, J.; Lin, L.; Li, E.; Keegan, S.; Lussier, J.; Wrocklage, C.; Nickerson-Nutter, C. L.; Wittwer, A. J.; Soutter, H.; Caspers, N.; Han, S.; Kurumbail, R.; Dunussi-Joannopoulos, K.; Douhan, J., 3rd; Wissner, A. Imidazo[1,5- a ]quinoxalines as irreversible BTK inhibitors for the treatment of rheumatoid arthritis Bioorg. Med. Chem. Lett. 2011, 21, 6258-6263
55. Currie, K. S.; Desimone, R. W.; Pippin, D. A.; Darrow, J. W.; Mitchell, S. A. Preparation of Imidazo[1,2- a ]pyrazin-8-ylamines as Kinase Modulators, Particularly Btk Inhibitors, for Treating Btk-Related Diseases and Conditions. Patent Application WO 2005/047290, 2005.
56. Currie, K. S.; Desimone, R. W.; Mitchell, S. A.; Pippin, D. A.; Darrow, J. W.; Qian, X.; Velleca, M.; Qian, D. Preparation of Imidazo[1,2- a ]pyrazin-8-ylamines for Inhibition of Bruton's Tyrosine Kinase. Patent Application WO 2005/014599, 2005.
57. Currie, K. S.; Desimone, R. W.; Mitchell, S.; Pippin, D. A. Preparation of Imidazo[1,2- a ]pyrazin-8-ylamines as Bruton's Tyrosine Kinase (Btk) Inhibitors for the Treatment of Cancer. Patent Application WO 2005/005429, 2005.
58. Currie, K. S. Targeting B-cells in inflammatory disease Annu. Rep. Med. Chem. 2010, 45, 175-190
59. Currie, K. S. Discovery and Optimization of a Novel Series of Highly Selective Inhibitors of Bruton's Tyrosine Kinase. Presented at the EFMC 21st International Symposium on Medicinal Chemistry, Brussels, Belgium, 2010.
60. Liu, L.; Di Paolo, J.; Barbosa, J.; Rong, H.; Reif, K.; Wong, H. Antiarthritis effect of a novel Bruton's tyrosine kinase (BTK) inhibitor in rat collagen-induced arthritis and mechanism-based pharmacokinetic/pharmacodynamic modeling: relationships between inhibition of BTK phosphorylation and efficacy J. Pharmacol. Exp. Ther. 2011, 338, 154-163
61. Liu, L.; Halladay, J.; Shin, Y.; Wong, S.; Coraggio, M.; La, H.; Baumgardner, M.; Le, H.; Gopaul, S.; Boggs, J.; Kuebler, P.; Davis, J.; Liao, C.; Lubach, J.; Deese, A.; Sowell, G.; Currie, K.; Young, W.; Khojasteh, C.; Hop, C.; Wong, H. Significant species difference in amide hydrolysis of GDC-0834, a novel potent and selective Bruton's tyrosine kinase (BTK) inhibitor Drug Metab. Dispos. 2011, 21742900
62. Dewdney, N. J.; Kondru, R. K.; Lou, Y.; Soth, M.; Gabriel, T. BTK Protein Kinase Inhibitors. Patent Application US 2009/0105209, 2009.
63. Dewdney, N. J.; Lou, Y.; Soth, M. Novel Imidazo[1,2-A]pyridine and Imidazo[1,2-B]pyridazine Derivatives. Patent Application WO 2009/077334, 2009.
64. Dewdney, N. J.; Kennedy-Smith, J.; Kondru, R. K.; Loe, B. E.; Lou, Y.; McIntosh, J.; Owens, T. D.; Soth, M.; Sweeney, Z. K.; Taygerly, J. P. G. Inhibitors of Bruton's Tyrosine Kinase. Patent Application US 2009/0306041, 2009.
65. Dewdney, N. J.; Lou, Y.; Sjogren, E. B.; Soth, M. Novel Phenyl-imidazopyridines and Pyridazines. Patent Application WO 2010/006947, 2010.
66. Dewdney, N. J.; Lou, Y.; Sjogren, E. B.; Soth, M.; Sweeney, Z. K. Novel Phenylpyrazinones as Kinase Inhibitors. Patent Application WO 2010/000633, 2010.
67. Dewdney, N. J.; Hawley, R. C.; Kondru, R. K.; Lai, Y.; Lou, Y. Inhibitors of Bruton's Tyrosine Kinase. Patent Application WO 2010/122038, 2010.
68. Berthel, S.; Firooznia, F.; Fishlock, D.; Hong, J.; Lou, Y.; Lucas, M.; Owens, T. D.; Sarma, K.; Sweeney, Z. K.; Taygerly, J. P. G. Inhibitors of Bruton's Tyrosine Kinase. Patent Application US 2010/0222325, 2010.
69. Xu, D.; Kim, Y.; Postelnek, J.; Vu, M. D.; Hu, D.-Q.; Hsu, J.; Liao, C.; Zhang, J.; Pashine, A.; Srinivasan, D.; Woods, J.; Owens, T.; Lou, Y.; Hill, R.; Narula, S.; DeMartino, J.; Fine, J. S. RN486 [6-cyclopropyl-8-fluoro-2-(2- hydroxymethyl-3-{1-methyl-5-[5-(4-methyl-piperazin-1-yl)-pyridin-2-ylamino] -6-oxo-1,6-dihydro-pyridin-3-yl}-phenyl)-2 H -isoquinolin-1-one], a selective Bruton's tyrosine kinase (Btk) inhibitor, abrogates immune hypersensitivity responses and arthritis in rodents. J. Pharmacol. Exp. Ther. 2012, 341, 90.
70. Lindauer, M.; Hochhaus, A. Dasatinib Recent Results Cancer Res. 2010, 184, 83-102
71. Hantschel, O.; Rix, U.; Schmidt, U.; Burckstummer, T.; Kneidinger, M.; Schutze, G.; Colinge, J.; Bennett, K. L.; Ellmeier, W.; Valent, P.; Superti-Furga, G. The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib Proc. Natl. Acad. Sci. U.S.A. 2007, 104, 13283-13288 (Pubitemid 47293937)
72. Sillaber, C.; Herrmann, H.; Bennett, K.; Rix, U.; Baumgartner, C.; Bohm, A.; Herndlhofer, S.; Tschachler, E.; Superti-Furga, G.; Jager, U.; Valent, P. Immunosuppression and atypical infections in CML patients treated with dasatinib at 140 mg daily Eur. J. Clin. Invest. 2009, 39, 1098-1109
73. Kneidinger, M.; Schmidt, U.; Rix, U.; Gleixner, K. V.; Vales, A.; Baumgartner, C.; Lupinek, C.; Weghofer, M.; Bennett, K. L.; Herrmann, H.; Schebesta, A.; Thomas, W. R.; Vrtala, S.; Valenta, R.; Lee, F. Y.; Ellmeier, W.; Superti-Furga, G.; Valent, P. The effects of dasatinib on IgE receptor-dependent activation and histamine release in human basophils Blood 2008, 111, 3097-3107
74. Liu, Q.; Batt, D. G.; DeLucca, G. V.; Shi, Q.; Tebben, A. J. Carbazole Carboxamide Compounds Useful as Kinase Inhibitors. Patent Application US 2010/0160303, 2010.
75. Liu, C.; Leftheris, K.; Tebben, A. J. Fused Heterocyclic Compounds Useful for the Treatment of Proliferative, Allergic, Autoimmune or Inflammatory Diseases. Patent Application WO 2008/116064, 2008.
76. Liu, C.; Leftheris, K.; Tebben, A. J. Fused Heterocyclic Compounds Useful as Kinase Modulators. Patent Application WO 2010/011837, 2010.
77. Duan, J.; Jiang, B.; Lu, Z. Azaindazoles as BTK Kinase Modulators and Use Thereof. Patent Application WO 2011/019780, 2011.
78. Bui, M.; Conlon, P.; Erlanson, D. A.; Fan, J.; Guan, B.; Hopkins, B. T.; Ishchenko, A.; Jenkins, T. J.; Kumaravel, G.; Marcotte, D.; Powell, N.; Scott, D.; Taveras, A.; Wang, D.; Zhong, M. Heteroaryl BTK Inhibitors. Patent Application WO 2011/029043, 2011.
79. Erlanson, D. A.; Marcotte, D.; Kumaravel, G.; Fan, J.; Wang, D.; Cuervo, J. H.; Silvian, L.; Powell, N.; Bui, M.; Hopkins, B. T.; Taveras, A.; Guan, B.; Conlon, P.; Zhong, M.; Jenkins, T. J.; Scott, D.; Lugovskoy, A. A. Bruton's Tyrosine Kinase Inhibitors. Patent Application WO 2011/029046, 2011.